Partnering with Dr Reddy’s will give Fujifilm “excellent capability in developing and manufacturing across active pharmaceutical ingredients (API) and formulations of generic drugs”, said Shigetaka Komori, president and CEO of Fujifilm.
In return, Fujifilm will use quality control techniques developed for its photo film business to support Dr Reddy’s Japanese expansion.
“Through Fujifilm's superior material process technology and quality control system, we aim to contribute to the adoption of high quality and affordable generic drugs in Japanese market”, said Komori.
The partners plan to launch a product in Japan within the next four years. Dr Reddy’s has a 49 per cent stake in the joint venture, with Fujifilm accounting for the rest.